Role of fesoterodine in the treatment of overactive bladder

Open Access Journal of Urology

Volumn 2, Issue 1, 2010, Pages 1-9

  Mansfield, Kylie J ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

5 hydroxymethyl tolterodine; Fesoterodine; Incontinence; Muscarinic; Overactive bladder; Urgency

Indexed keywords

5 HYDROXYMETHYLTOLTERODINE; CYTOCHROME P450 2D6; DARIFENACIN; DRUG METABOLITE; FESOTERODINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; UNCLASSIFIED DRUG;

BLADDER FUNCTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSTIPATION; COST OF ILLNESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; HUMAN; MICTURITION DISORDER; NONHUMAN; OVERACTIVE BLADDER; PROTEIN FUNCTION; QUALITY OF LIFE; QUESTIONNAIRE; RADIOASSAY; REVIEW; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TREATMENT DURATION; URINARY URGENCY; URINE VOLUME; XEROSTOMIA;

EID: 77953409468     PISSN: None     EISSN: 11791551     Source Type: Book Series    
DOI: None     Document Type: Review

References (93)

1. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-766.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6): 327-336.
3. Abrams P, Cardozo L, Fall M, et al; For Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-178.
4. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(6 Suppl 1):2-6.
5. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6): 1123-1128.
6. Brubaker L. Urgency: the cornerstone symptom of overactive bladder. Urology. 2004;64(6 Suppl 1):12-16.
7. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987-1006.
8. Andersson KE, Yoshida M. Antimuscarinics and the overac- tive detrusor-which is the main mechanism of action? Eur Urol. 2003;43(1):1-5.
9. Hegde SS, Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol. 2006;147(Suppl 2):S80-S87.
10. Ferguson DR, Kennedy I, Burton TJ. ATP is released from rabbit uri- nary bladder epithelial cells by hydrostatic pressure changes - a possible sensory mechanism? J Physiol. 1997;505(2):503-511.
11. Downie JW, Dean DM. The contribution of cholinergic postganglionic neurotransmission to contractions of rabbit detrusor. J Pharmacol Exp Ther. 1977;203(2):417-425.
12. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50(2):279-290.
13. Eglen RM, Hegde S, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996;48(4):531-565.
14. Nilvebrant L, Andersson KE, Mattiasson A. Characterization of the muscarinic cholinoceptors in the human detrusor. J Urol. 1985;134(2): 418-423.
15. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995;273(2):959-966.
16. Goepel M, Gronewald A, Krege S, et al. Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. Urol Res. 1998;26(2):149-154.
17. Mansfield KJ, Liu L, Mitchelson FJ, et al. Muscarinic receptor sub- types in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol. 2005;144(8):1089-1099.
18. Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Nat Acad Sci U S A. 2000;97(17):9579-9584.
19. Chess-Williams R, Chapple CR, Yamanishi T, et al. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol. 2001;21(5-6):243-248.
20. Fetscher C, Fleichman M, Schmidt M, et al. M(3) muscarinic recep- tors mediate contraction of human urinary bladder. Br J Pharmacol. 2002;136(5):641-643.
21. Matsui M, Motomura D, Fujikawa T, et al. Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci. 2002;22(24): 10627-10632.
22. Ehlert FJ. Contractile role of M2 and M3 muscarinic receptors in gastrointestinal, airway and urinary bladder smooth muscle. Life Sci. 2003;74(2-3):355-266.
23. Fredericks CM, Green RL, Anderson GF. Comparative in vitro effects of imipramine, oxybutynin, and flavoxate on rabbit detrusor. Urology. 1978;12(4):487-491.
24. Paulson DF. Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. Urology. 1978;11(3):237-238.
25. Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urology. 1980;52(6):472-475.
26. Bary PR, Moisey CU, Stephenson TP, et al. The urodynamic and subjec- tive results of treatment of detrusor instability with oxybutynin chloride. Prog Clin Biol Res. 1981;78:313-319.
27. Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol. 1997;81(4):169-172.
28. Van Kerrebroeck P, Kreder K, Jonas U, et al; For Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57(3):414-421.
29. Sussman D, Garely A. Treatment of overactive bladder with once- daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Cur Med Res Opin. 2002;18(4): 177-184.
30. Diokno AC, Appell RA, Sand PK, et al; For the OPERA Study Group., Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687-695.
31. Kaplan SA, Roehrborn CG, Dmochowski R, et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68(2):328-332.
32. Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol. 2007;51(4):1054-1064.
33. Andersson SH, Lindgren A, Postlind H. Biotransformation of toltero- dine, a new muscarinic receptor antagonist, in mice, rats, and dogs. Drug Met Disp. 1998;26(6):528-535.
34. Postlind HD, Lindgren A, Andersson SH. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Met Disp. 1998;26(4):289-293.
35. Palmér L, Andersson L, Andersson T, et al. Determination of toltero- dine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry. J Pharm Biomed Anal. 1997;16(1):155-165.
36. Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characteriza- tion of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008;101(8):1036-1042.
37. Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology. 2008;71:839-843.
38. Michel MC, Hedge S. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol. 2006;374(2):79-85.
39. Brynne N, Dalén P, Alván G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998;63(5):529-539.
40. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol. 2001;41:851-850.
41. Simon HU, Malhotra B. The pharmacokinetic profile of fesotero- dine: similarities and differences to tolterodine. Swiss Med Weekly. 2009;139(9-10):146-151.
42. Malhotra B, Gandelman K, Sachse R, et al. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. J Clin Pharmacol. 2009;49(4):477-482.
43. Sachse R, Cawello W, Haag C, et al. Pharmacodynamics and pharma- cokinetics of ascending multiple doses of the novel bladder-selective antimuscarinic fesoterodine. Eur Urol. 2003;2(1):30.
44. Cawello W, Auer S, Hammes W, et al. Multiple dose pharmacokinet- ics of fesoterodine in human subjects. Naunyn-Schmiedeberg's Arch Pharmacol. 2002;365(Suppl 1):R110.
45. Malhotra B, Sachse R, Wood N. Evaluation of drug-drug interactions with fesoterodine. Eur J Clin Pharmacol. 2009;65(6):551-560.
46. Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fes- oterodine. Int J Clin Pharmacol Ther. 2008;46(11):556-563.
47. Chapple C, V Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204-1212.
48. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and toler- ability of Fesoterodine for overactive bladder syndromes. J Urol. 2007;178:2488-2494.
49. Sand PK, Morrow J, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynaecol J. 2009;20:827-835.
50. Larsson G, Hallén B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology. 1999;53(5):990-998.
51. Millard R, Tuttle J, Moore KH, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol. 1999;161(5):1551-1555.
52. Van Kerrebroeck PE, Amarenco G, Thüroff JW, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn. 1998;17(5):499-512.
53. Hill S, Khullar V, Wyndaele JJ, et al; For the Darifenacin Study Group. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct. 2006;17:239-247.
54. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919-1924.
55. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997;104(12):1374-1279.
56. Chapple CR, Van Kerrebroeck P, Jünemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008;102(9):1128-1132.
57. Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int. 2008;102(1): 56-61.
58. Kelleher CJ, Pleil A, Reese PR, et al. How much is enough and who says so? BJOG. 2004;111(6):605-612.
59. Morris AR, Westbrook J, Moore KH. A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor over-activity. BJOG. 2008;115(2):239-246.
60. Colli E, Digesu G, Olivieri L. Overactive bladder treatments in early phase clinical trials. Exp Opin Invest Drugs. 2007;16(7):999-1007.
61. Martos F, Bermudez R, Gomez A, et al. Characterization of muscarinic receptors in human submandibular salivary glands. Eur J Pharmacol. 1985;116(3):319-321.
62. Mansfield KJ, Mitchelson F, Moore KH, et al. Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes. Eur J Pharmacol. 2004;482(1-3):101-109.
63. Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009;63(4):560-567.
64. Chapple CR, Fianu-Jonsson A, Indig M, et al; For the STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007;52(4):1195-1203.
65. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol. 2005;23(4):248-252.
66. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol. 1997; 327(2-3):195-207.
67. Freeman R, Hill S, Millard R, et al; For the Tolterodine Study Group. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynaecol. 2003;102(3): 605-611.
68. Chapple CR, Araño P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor over- activity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int. 2004;93(1):71-77.
69. Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin. 2006;22(1):41-48.
70. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother. 2006;4(1):14-24.
71. Zinner N, Gittelman M, Harris R, et al; For the Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multi- center phase III trial. J Urol. 2004;171(6 pt 1):2311-2315.
72. Finney SM, Andersson KE, Gillespie JI, et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98(3):503-507.
73. Hawthorn MH, Chapple CR, Cock M, et al. Urothelium-derived inhibi- tory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol. 2000;129(3):416-419.
74. Bschleipfer T, Schukowski K, Weidner W, et al. Expression and dis- tribution of cholinergic receptors in the human urothelium. Life Sci. 2007;80(24-25):2303-2307.
75. Tyagi S, Tyagi P, Van-le S, et al. Qualitative and quantitative expres- sion profile of muscarinic receptors in human urothelium and detrusor. J Urol. 2006;176(4 pt 1):1673-1678.
76. Mukerji G, YiangouY, Grogono J, et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol. 2006;176(1):367-373.
77. Grol S, Essers P, van Koeveringe GA, et al. M(3) muscarinic receptor expression on suburothelial interstitial cells. BJU Int. 2009;104(3): 398-405.
78. Kim Y, Yoshimura N, Masuda H, et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005;65(2):238-242.
79. de Wachter S, Wyndaele JJ. Intravesical oxybutynin: A local anaesthetic effect on bladder C afferents. J Urol. 2003;169:1892-1895.
80. Yokoyama O, Yusup A, Miwa Y, et al. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol. 2005;174(5):2032-2036.
81. Iijima K, de Wachter S, Wyndaele JJ. Effects of the M3 receptor selec- tive muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol. 2007;52(3):842-847.
82. de Laet K, de Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn. 2006; 25(2):156-161.
83. Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia. 1991;29(2):84-90.
84. Lose G, Nørgaard JP. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. BJU Int. 2001;87(9):767-773.
85. Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary blad- der and salivary gland. Naunyn-Schmiedeberg's Arch Pharmacol. 2002;366(2):97-103.
86. Moriya H, Takagi Y, Nakanishi T, et al. Affinity profiles of various mus- carinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-2358.
87. Watson N, Daniels DV, Ford AP, et al. Comparative pharmacology of recombinant human M3 and M5 muscarinic receptors expressed in CHO-K1 cells. Br J Pharmacol. 1999;127(2):590-596.
88. McNamara A, Pulido-Rios MT, Sweazey S, et al. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol. 2009;605(1-3):145-153.
89. Ohtake A, Saitoh C, Yuyama H, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull. 2007;30(1):54-58.
90. Nilvebrant L, Sundquist S, Gillberg PG. Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo. Neurourol Urodyn. 1996;15:310-311.
91. Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998;349(2-3):285-292.
92. Mansfield KJ, Chandran J, Vaux KJ, et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther. 2009;328(3):893-899.
93. Ito Y, Oyunzul L, Yoshida A, et al. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and subman- dibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009;615(1-3):201-206.